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Objective: Statins possess anti-inﬂammatory properties. This study was undertaken to characterize the
mechanism of action of statin drugs on collagenase expression in primary human osteoarthritic cartilage
tissue.
Method: Human articular chondrocytes and cartilage explants from osteoarthritic donors were exposed
to simvastatin in the presence or absence of interleukin-1 beta (IL-1b). Collagenase expression was
determined by quantifying levels of matrix metalloproteinase 13 (MMP-13) and MMP-1 mRNA and
MMP-13 protein. The mechanism of statin action was tested by addition of farnesyl pyrophosphate (FPP)
and geranylgeranyl pyrophosphate (GGPP) or by using inhibitors of farnesyl transferase (FT) and ger-
anylgeranyl transferase (GGT-1).
Results: Treatment of osteoarthritic chondrocytes with simvastatin decreased mRNA levels of MMP-13
and MMP-1 whether under basal conditions or during stimulation with IL-1b. MMP-13 protein secreted
into the culture media was also decreased. Genes involved in cartilage synthesis (type II collagen and
aggrecan) were not down-regulated by simvastatin. Exogenous addition of GGPP completely reversed the
statin-mediated decrease in MMP-13 mRNA and protein levels whereas FPP partially reversed the statin-
mediated effect. An inhibitor of GGT-1 mimicked the simvastatin-mediated reduction in MMP-13
expression by chondrocytes. Finally, consistent with impacts on MMP-13 and MMP-1 expression, sim-
vastatin as well as the GGT-1 inhibitor both blocked type II collagen degradation in primary human
articular cartilage explants.
Conclusion: These results suggest that statins modulate chondrocyte metabolism by reducing prenylation
of key signaling molecules that control the expression of collagen-degrading enzymes. Our results
strongly support the hypothesis that protein prenyltransferases including geranylgeranyl transferase
regulate chondrocyte collagenase expression in osteoarthritis.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a progressive degenerative disease of
articular cartilage that is characterized by proteolytic degradation
of key structural proteins and the subsequent loss of cartilage.
Much work has been done to elucidate the roles of catabolic
enzymes including the aggrecanases1 and collagenases2 in the
breakdown of cartilage structure. The role of collagenases in
mediating the breakdown of type II collagen, the major structural: Francis M. Sverdrup, Pﬁzer
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s Research Society International. Pcollagen of articular cartilage, during the progression of OA is well
established. MMP-13 expressed by chondrocytes residing in carti-
lage as well as MMP-1 which is secreted by synovial cells are both
able to cleave type II collagen2. MMP-13 is particularly potent in its
ability to cleave type II collagen and is considered to play a prom-
inent role in the joint destruction associated with OA3,4. The
importance of chondrocyte MMP-13 expression in the destruction
of cartilage is highlighted by the immunolocalization of both MMP-
13 protein and MMP-13-speciﬁc type II collagen cleavage products
around superﬁcial zone chondrocytes in regions of matrix degra-
dation in OA cartilage5,6.
MMP-13 expression in chondrocytes is induced by a number of
catabolic and inﬂammatory stimuli. The cytokines IL-1 and tumor
necrosis factor-a (TNF-a) play central roles in cartilage catabolism
in OA and both stimulate the production of a number of catabolic
proteases in chondrocytes including MMP-137e12. Other cytokinesublished by Elsevier Ltd. All rights reserved.
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oncostatin M (OSM)14, IL-1715 and IL-1816. Matrix breakdown
products including those derived from ﬁbronectin17e19 and type II
collagen20,21 also stimulate the expression of MMP-13 in chon-
drocytes. Additionally, advanced glycation end products (AGEs) and
the S100A4 protein stimulate MMP-13 expression by interacting
with the receptor for AGE (RAGE)22e24. Finally, mechanical stress
can induce changes in chondrocyte gene expression including
induction of MMP-1325e27. It is clear that a number of diverse
signaling pathways converge to support transcription of the MMP-
13 gene in chondrocytes and that a comprehensive understanding
of these pathways may lead to new approaches for modulating
collagenase expression in disease states.
Inhibitors of the cholesterol biosynthetic pathway enzyme
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase,
referred to as statins, have both lipid lowering and non-lipid
lowering pharmacological properties. Those properties that are
independent of lipid lowering include a broad range of immuno-
modulatory and anti-inﬂammatory effects (for review, see28). These
“pleiotropic” effects occur in a number of different cell types
including endothelial cells, monocytes, macrophages, vascular
smooth muscle cells and T-lymphocytes. For example, in the
context of atherosclerosis, statins diminish inﬂammation by
decreasing leukocyte migration and adhesion29, by decreasing the
expression of monocyte adhesion molecules on endothelial cells30,
by preventing the downregulation of endothelial nitric oxide syn-
thase31 and by reducing IL-6 and IL-8 expression by vascular
smooth muscle cells32,33. In addition, statins inhibit matrix metal-
loproteinase (MMP-9) expression by activated macrophages that
accumulate in atherosclerotic plaques34. Thus, it appears that sta-
tins possess a unique and potent ability to modulate inﬂammatory
gene expression in a number of settings.
The mechanism by which statins exert pleiotropic effects in
different cell types appears to be linked to the inhibition of
mevalonate synthesis. In addition to reducing cholesterol synthesis,
inhibition of HMG-CoA reductase also targets other intermediates
of the cholesterol biosynthetic pathway such as mevalonate as well
as downstream metabolites including the isoprenoids FPP and
GGPP (Fig. 1). The reduction of FPP and GGPP and subsequently theHMG-CoA
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Fig. 1. The normal structure and function of small GTP-binding proteins (dark blue boxes)
inhibit the synthesis of mevalonate and thus have the potential to interfere with the functi
enzymes posttranslationally modify small GTP-binding proteins by attaching speciﬁc isopr
inhibitors of farnesylation and geranylgeranylation (FTi and GGTi) target distinct subsets of
mevalonate metabolism. Additionally, pathway intermediates like farnesyl pyrophosphate (F
of action of statins on particular aspects of chondrocyte metabolism.farnesylation and geranylgeranylation of small guanosine triphos-
phate (GTP)-binding proteins have been directly linked to the
mechanism of statin action in non-hepatic cell types28. For
example, the statin-mediated decrease in IL-6 and IL-8 expression
by vascular smooth muscle cells is reversed by the addition of
GGPP, suggesting that the statin effect is mediated by a decrease in
the geranylgeranylation of a Rho family GTPase32,33.
A limited number of studies have addressed the effects of statins
in the context of osteoarthritic disease. In one study, simvastatin
was shown to inhibit the extracellular production of MMP-3 from
human OA chondrocytes in both the absence and presence of
stimulation with exogenously added IL-135. In another study, sim-
vastatin inhibited the production of IL-6 and IL-8 from isolated
human chondrocytes and cartilage explants treated with IL-1 and
TNF-a36. Neither of these studies directly addressed the effects of
statin treatment on chondrocyte gene expression. Recently, ator-
vastatin was shown to reduce MMP-13 mRNA in chondrocytes
isolated from osteoarthritic cartilage37. Additionally, mevastatin
administered by intra-articular injection reduced cartilage degra-
dation in a rabbit anterior cruciate ligament transection (ACLT)
model of OA38. However, chondroprotection in that study was
attributed to inhibition of synovial inﬂammation and effects on
chondrocyte gene expression were not observed. We began studies
in primary human chondrocytes and cartilage to address the
hypothesis that statins may have beneﬁcial effects on cartilage
including the downregulation of collagenase (MMP-13, MMP-1)
gene expression and enzyme production in chondrocytes.
Methods
Human OA chondrocytes
Human articular cartilage was obtained from OA donors
(Asterand, Detroit, MI). Chondrocytes were isolated using pro-
nase/collagenase digestion and then cultured in alginate beads
prior to experimentation. For our studies, chondrocytes were
plated in high-density monolayer under serum-free conditions
(80,000 cells/well in 96-well tissue culture-treated plates). Cells
were pre-treated with test compounds for 24 h prior toFarnesyl
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ranylgeranyl
ransferase
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require the ready intracellular provision of mevalonate-derived intermediates. Statins
on of these cell signaling proteins. Farnesyl transferase and geranylgeranyl transferase
enoid moieties (farnesyl and geranylgeranyl, respectively) onto the proteins. Selective
signaling molecules and thus avoid potential complications of disrupting all aspects of
PP) and geranylgeranyl pyrophosphate (GGPP) are useful to investigate the mechanism
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MN). Media were removed following pre-treatment and replaced
with media containing fresh compoundþ/ IL-1b. Following a 24-
h cytokine stimulation, media were collected, RNA isolated, and
gene expression assayed using Taqman RT-PCR. Assays speciﬁc for
individual genes were obtained from Applied Biosystems as
“Assays on Demand” and Taqman RT-PCR reactions were run on
an Applied Biosystems 7900HT instrument. Gene expression
results are displayed as mean (n¼ 3) relative expression 95%
conﬁdence intervals normalized to the expression of Cyclophilin
A. MMP-13 protein in culture supernatants was assayed by
Enzyme-linked immunosorbent assay (ELISA) (R&D Systems,
Minneapolis, MN). Simvastatin was obtained from Sigma
(St. Louis, MO) and was used at a concentration of 10 mM unless
indicated differently in ﬁgure or table legends. Geranylgeranyl
pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) were
purchased from Sigma and used at concentrations of 5 mM.
Y-27632 was obtained from Sigma. Y-27632 is a cell-permeable
Rho kinase inhibitor (ROCKi) and was used at a concentration of
5 mM. GGTi-2147 and FTi-2628 were obtained from EMD Biosci-
ences. GGTi-2147 is a cell-permeable pro-drug of the geranylger-
anyl transferase inhibitor GGTi-2133. The IC50 of GGTi-2147 in
cultured cells is w500 nM while the IC50 of GGTi-2133 in an
enzyme assay is 38 nM39,40. GGTi-2147 was used at a ﬁnal
concentration of 5 mM. FTi-2628 is a cell-permeable pro-drug
form of the farnesyl transferase inhibitor FTi-2148. The IC50 of FTi-
2628 in cultured cells has been reported to range from 20 to
250 nM while the IC50 of FTi-2148 for enzyme is 530 nM41,42. FTi-
2628 was used at a ﬁnal concentration of 5 mM. All compounds
were dissolved in DMSO to create 1000 stocks before dilution
into culture media. All cultures including controls contained
a ﬁnal concentration of 0.1% DMSO.
The simvastatin used in these studies (lactone ring form) was
not activated by hydrolysis to the active b-hydroxy acid prior to use.
The consistency of results presented here in terms of effects by
simvastatin that were reversed by either GGPP or FPP indicates that
simvastatin was activated in the culture systems and was acting
through inhibition of mevalonate biosynthesis. This conclusion is
further supported by data inwhich the inhibition of geranylgeranyl
transferase produced results consistent with inhibition by simvas-
tatin and reversal by addition of GGPP. Enzymes present in human
serum that catalyze the hydrolysis of simvastatin to the active
b-hydroxy acid form are called paraoxonases43. Although serum
was not used in these experiments, paraoxonases have been
immunolocalized to chondrocytes of hyaline cartilage in mice44.
Additionally, chondrocytes within human normal as well as OATable I
Key gene expression changes in simvastatin-treated chondrocytes from OA donors.
IL-1 Sim (mM) MMP-13y MMP-1y ADAM-TS5y ADAM
- Control 1.03 0.21 1.05 0.20 0.94 0.25 1.20
 0.1 0.71 0.17 0.79 0.04 0.86 0.12 1.46
 0.3 0.64 0.09* 0.78 0.07* 0.75 0.08 1.26
 0.9 0.27 0.19* 0.60 0.11* 0.49 0.08* 1.43
 2.7 0.29 0.03* 0.48 0.01* 0.28 0.02* 1.21
 8.1 0.16 0.01* 0.34 0.02* 0.15 0.01* 1.46
þ Control 3.39 1.49 9.98 3.83 2.97 0.99 1.64
þ 0.1 2.98 0.60 10.04 0.63 2.73 0.29 1.35
þ 0.3 2.66 0.55 6.10 0.67 2.01 0.06 1.47
þ 0.9 2.02 0.33 6.60 0.80 1.57 0.23# 1.65
þ 2.7 1.35 0.43# 4.17 0.78# 0.96 0.17# 1.34
þ 8.1 0.79 0.35# 2.75 0.20# 0.47 0.06# 2.18
y Means of n¼ 3 relative mRNA expression ( 95% conﬁdence intervals)
* p< 0.05 for signiﬁcant difference from control (No IL-1) based on a one-sided t-test
# p< 0.05 for signiﬁcant difference from control (þIL-1) based on a one-sided t-testcartilage express mRNA for paraoxonases (Sverdrup, FM, unpub-
lished data). Thus, it appears that chondrocytes possess the ability
to convert simvastatin to its active metabolite.
Cartilage protection ex vivo
Human articular cartilage (HAC) was dissected from knees
obtained from OA patients undergoing knee replacement
(Asterand, Detroit, MI). Apparently normal (not ﬁbrillated)
cartilage was cut into small pieces (w2 mm) and cultured in 96-
well plates with 200 ml of Dulbecco’s modiﬁed Eagle’s medium
(DMEM) media (Gibco BRL high glucose, 25 mM HEPES, con-
taining 2 mM L-glutamine and 1 mM sodium pyruvate) freshly
supplemented with 1 HL-1 (LONZA) and 5 mg/ml ascorbic acid
(Sigma), with or without 0.1 ng/ml IL-1b (R &D Systems, Minne-
apolis, MN)þ 50 mg/ml Oncostatin M (R & D Systems). Cartilage
wells (n¼ 10/condition) were incubated in the absence or pres-
ence of serially diluted test compounds, which were added 24 h
prior to cytokine stimulation. Media were replaced every 3e4
days and cartilage was cultured for a total of 18 days. Conditioned
media were stored at 20C until analysis for type II collagen
neo-epitope (TIINE) peptides.
TIINE sandwich immunoassay
Samples were analyzed using a chemiluminescent sandwich
immunoassay consisting of the neo-epitope 9A4 antibody (recog-
nizing the conserved sequence at the C-terminus of the 3/4 type II
collagen fragment GPPGPQG following collagenase cleavage) and
the capture 5109 antibody (recognizing the type II collagen-speciﬁc
epitope GEPGDDGPS) as detailed elsewhere45. The assay utilizes
the proprietary, chemiluminescent Bioveris technology (Bioveris
Corporation, Gaithersburg, MD), in which the sandwich format is
bound to a paramagnetic bead support phase in suspension, passed
through a ﬂow cell, and captured by a magnet. The process effec-
tively separates the analyte from the sample, decreasing back-
ground interference and eliminating wash steps required in other
formats. Brieﬂy, serially diluted cartilage supernatant samples were
assayed in a 96-well plate. In this one step assay, 25 ml of sample,
25 ml of streptavidin beads (0.4 mg/ml), 25 ml of each antibody at
1 mg/ml (Biotin conjugated mouse 5109 anti-capture and BVTAG
labeled 9A4 anti-neo-epitope) and 100 ml of assay buffer (DPBS,
0.1% BSA, 0.05% Tween 20, pH 7.4) were incubated for 2 h at room
temperature before reading on the Bioveris M384 Analyzer. Values
were calculated from a standard curve prepared from human
45-mer (0.125e10 ng/ml) neo-epitope peptide.TS4y INOSy IL-6y Collagen IIy Aggrecany
0.55 1.18 0.42 0.93 0.18 1.26 0.53 1.02 0.40
0.26 0.95 0.31 1.07 0.25 1.72 0.31 0.97 0.45
0.35 1.84 0.36 0.89 0.26 1.89 0.51 1.00 0.55
0.08 2.41 0.57 0.59 0.07 2.04 0.35* 1.11 0.38
0.10 2.13 0.90 0.60 0.17 2.11 0.26* 1.34 0.60
0.39 1.58 0.59 0.35 0.11 2.06 0.39* 1.47 0.28
0.21 18.34 3.53 33.39 11.76 0.86 0.37 0.51 0.15
0.35 16.98 4.88 22.84 9.40 0.97 0.22 0.63 0.24
0.19 25.89 3.04 19.65 3.86# 0.80 0.11 0.45 0.07
0.25 39.77 0.63# 19.92 2.33# 0.98 0.09 0.44 0.05
0.30 40.60 12.81# 19.07 8.98 1.30 0.61 0.77 0.54
0.89 60.70 31.26# 14.89 4.29# 1.86 0.63# 1.05 0.35
Table III
MMP-13 mRNA and protein expression in OA chondrocytes: effects of inhibitors.
Treatments MMP-13 mRNAy MMP-13 protein (ng/ml)y
No IL-1 Control 1.01 0.32 8.65 1.19
ROCKi 1.69 0.17 11.50 1.51
Simvastatin 0.31 0.04* 4.58 0.20*
GGTi 0.97 0.24 8.50 0.38
þIL-1 Control 11.65 4.27 76.25 7.38
ROCKi 14.48 2.20 105.30 7.45
Simvastatin 4.62 0.84# 49.54 2.89#
GGTi 8.21 0.44 54.51 1.13#
y Means of n¼ 3 (95% conﬁdence intervals).
* p< 0.05 for signiﬁcant difference from control (No IL-1) based on a one-sided
t-test.
# p< 0.05 for signiﬁcant difference from control (þIL-1) based on a one-sided
t-test.
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The one-way analysis of variance model was used in analyzing
the data. Following the signiﬁcant overall F-test, we conducted
pair-wise comparisons using the one-sided t-test to demonstrate
differences between individual treatment groups and control
samples (p< 0.05). Data are presented with errors as 95% conﬁ-
dence intervals as calculated by Microsoft Excel.
Results
We ﬁrst explored the effects of HMG-CoA reductase inhibition
on collagenase expression in human chondrocytes from osteoar-
thritic donors undergoing total knee replacement surgery. In the
presence or absence of stimulation by the cytokine IL-1b, simvas-
tatin treatment for 48 h resulted in a concentration-dependent
decrease in MMP-13 mRNA levels (Table I). The suppression of
MMP-13 expression was approximately 85% in the absence of
cytokine stimulation and 75% when IL-1 was used as a stimulus.
The estimated IC50 for this effect was 1 mM. These results were
similar for another collagenase that cleaves type II collagen, MMP-1.
To ensure that simvastatin was not exerting a global suppressive
effect on gene expression, themRNA levels of two genes of cartilage
anabolism, those for the structural proteins type II collagen and
aggrecan, were measured and found not to be suppressed. In fact,
an apparent increase in collagen II and aggrecan was observed.
Interestingly, simvastatin treatment resulted in a concentration-
dependent decrease in the mRNA levels of aggrecanase 2 (ADAM-
TS5) but did not affect the mRNA levels of aggrecanase 1
(ADAMTS4). Notably, simvastatin treatment did not suppress the
IL-1 stimulated expression of inducible nitric oxide synthase (iNOS)
while it did lower the IL-1 stimulated levels of interleukin-6 (IL-6)
by approximately 50%. These data were replicated in chondrocytes
from several donors and clearly demonstrate that statins have the
ability to down-regulate chondrocyte collagenase gene expression.
We next investigated the mechanism by which simvastatin
repressed MMP-13 mRNA expression by adding back cholesterol
pathway intermediates during simvastatin treatment. In OA chon-
drocytes not exposed to inﬂammatory cytokine, GGPP, but not
farnesyl pyrophosphate FPP, completely reversed the statin-medi-
ated repression of MMP-13 expression (Table II). Similar results
were achieved after induction of MMP-13 mRNA levels with IL-1b
after 24 h simvastatin pre-treatment. In the presence or absence of
IL-1b, FPP partially reversed the statin-mediated repression ofTable II
MMP-13 mRNA and protein expression in OA chondrocytes: reversal of simvastatin
effects by GGPP
Treatments MMP-13 mRNAy MMP-13 protein (ng/ml)y
No IL-1 Control 1.00 0.12 2.13 1.11
GGPP 3.01 0.79 6.29 0.81
FPP 1.75 0.35 3.96 0.32
Simv 0.29 0.05 1.20 0.07
SimvþGGPP 1.95 0.91* 5.49 0.21*
Simvþ FPP 0.69 0.30* 2.24 0.19*
þIL-1 Control 4.73 2.26 9.35 0.31
GGPP 6.54 3.18 14.30 0.98
FPP 7.22 2.81 11.33 1.85
Simv 0.91 0.39 5.06 0.68
SimvþGGPP 4.66 0.96# 10.98 1.44#
Simvþ FPP 3.11 1.41# 10.77 0.49#
y Means of n¼ 3 (95% conﬁdence intervals).
* p< 0.05 for signiﬁcant difference from simvastatin treatment (No IL-1, Simv)
based on a one-sided t-test.
# p< 0.05 for signiﬁcant difference from simvastatin treatment (þIL-1, Simv)
based on a one-sided t-test.MMP-13 expression. The MMP-13 mRNA levels were mirrored by
MMP-13 protein levels quantiﬁed in culture supernatants (Table II).
These results indicate that simvastatin decreases MMP-13 expres-
sion through a mechanism involving the depletion of the iso-
prenoids GGPP and FPP and suggest that GGPP plays a major role in
controlling MMP-13 expression.
The enzymes geranylgeranyl transferase and farnesyl trans-
ferase utilize GGPP and FPP, respectively, to isoprenylate a large
number of cellular proteins. To further elucidate the role of protein
prenylation, and speciﬁcally geranylgeranylation, in regulating
MMP-13 expression, experiments were performed with the ger-
anylgeranyl transferase inhibitor GGTi-2147. GGTi-2147 reduced
MMP-13 expression in IL-1b stimulated chondrocytes similarly to
simvastatin (Table III). These results were supported by a compa-
rable decrease in MMP-13 protein secreted into the culture media
(Table III). The Rho kinase inhibitor Y-27632 (ROCKi) did not inhibit
MMP-13 expression, suggesting that blockade of RhoA ger-
anylgeranylation is not involved in MMP-13 suppression. The
importance of geranylgeranylation to MMP-13 expression was
further supported by our inability to demonstrate decreased
expression of MMP-13 with the farnesyl transferase inhibitor FTi-
2628 (data not shown). These data thus suggest that protein ger-
anylgeranylation catalyzed by the enzyme GGT plays a major role in
MMP-13 expression in chondrocytes isolated from OA cartilage.
To more rigorously assess the role of protein geranylger-
anylation in mediating the expression of collagenases responsible
for cartilage destruction, we utilized human osteoarthritic cartilage
explants that were treated for 18 days with IL-1b and OSM. In this
model of OA pathology, degradation of type II collagen is observed
between 7 and 21 days of cytokine treatment. Collagen fragments
speciﬁc to MMP-13 cleavage are released into the culture super-
natants46e48 and can be quantiﬁed using the collagen Type II neo-
epitope (TIINE) immunoassay49. Whereas there was a low level of
TIINE release from cartilage explants in the absence of cytokine,
exogenously added IL-1b plus OSM greatly stimulated the release of
TIINE beginning after day 7 and increasing through day 18 [Fig. 2
(A)]. Simvastatin treatment signiﬁcantly reduced TIINE release by
cytokine-stimulated explants at both 1 mM and 10 mM concentra-
tions. In contrast, farnesyl transferase inhibition had only a minor
effect [Fig. 2(A)]. Importantly, the geranylgeranyl transferase
inhibitor GGTi-2147 inhibited TIINE release in a concentration-
dependent manner [Fig. 2(B)]. These data demonstrate that statin
treatment and the inhibition of protein geranylgeranylation each
effectively block collagen degradation in a human cartilage explant
model of OA. In addition to collagen, proteoglycans including
aggrecan are degraded in cytokine-treated cartilage explants. Since
it was observed that simvastatin treatment of chondrocytes in
culture resulted in decreased expression of one of the aggrecanases
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Fig. 2. Collagen type II degradation in IL-1b- and oncostatin M-treated human articular cartilage explants. Human articular cartilage explants (n¼ 10/condition) were incubated
with the indicated compounds starting 24 h prior to exposure to IL-1bþ oncostatin M at day 0. Fragmented type II collagen was measured in supernatants using the collagen Type II
neo-epitope (TIINE) assay. Values are plotted with error bars representing 95% conﬁdence intervals. (A) Control (IL-1þOSM), simvastatin and FTi-2628 treatment. (B) Control
(IL-1þOSM) and GGTi-2147 treatment. Day 18 TIINE values were subject to statistical analyses. *p< 0.05.
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supernatants of cartilage explants. Il-1b/OSM-induced proteo-
glycan release was decreased by both simvastatin and the GGT
inhibitor only during the early phase of the culture (days 1e3). At
all later time points through day 18, there was no inhibition (data
not shown).
Discussion
Studies of macrophages that accumulate in atherosclerotic pla-
ques ﬁrst suggested that statins had the ability to modulate matrix
metalloproteinase expression34. In addition to effects on macro-
phages, statins have also been shown to inhibit MMP production
from other cell types including vascular smooth muscle cells,
osteoblasts and ﬁbrosarcoma cells50,51. These data have led others
to speculate that statins may decrease the production by chon-
drocytes of MMPs that breakdown articular cartilage and may
therefore provide a therapeutic beneﬁt for osteoarthritic disease52.
Indeed, statin treatment applied to isolated chondrocytes has been
shown to modulate the expression of MMP-3 and MMP-1335,37.
We have examined in greater detail the effects of simvastatin on
chondrocytes in the context of OA. In particular we focused on
MMP-13 and MMP-1 which are the principal collagenases thattarget type II collagen for degradation. Our data clearly demon-
strate that simvastatin reduced the expression of MMP-13 and
MMP-1 by human OA chondrocytes whether in the context of basal
levels of expression or the increased levels resulting from cytokine-
mediated stimulation. Repression of MMP expression was con-
centrationdependent with an estimated IC50 of w1 mmol/L. We
further illustrated the physiological signiﬁcance of reducingMMP-1
and MMP-13 expression by demonstrating that simvastatin blocks
collagen destruction in IL-1b/OSM-treated human OA cartilage
explants, a model that recapitulates several key features of OA
pathology. This key piece of data strongly suggests that the regu-
lation of MMP-13 expression by modulation of cholesterol
biosynthetic pathway intermediates will provide a therapeutic
beneﬁt in OA.
The complete reversal of statin-mediated effects on chon-
drocyte collagenase expression by GGPP suggests that protein
geranylgeranylation uniquely regulates key enzymes in the matrix
metalloproteinase family, especially those associated with joint
cartilage damage like MMP-13 and MMP-1. Partial reversal by FPP
suggests that protein farnesylation may also play a role in the
complex regulatory networks controlling MMP-13 expression.
Signiﬁcantly, GGTi-2147, a geranylgeranyl transferase inhibitor, also
blocked collagen destruction in IL-1b/OSM-treated human OA
F.M. Sverdrup et al. / Osteoarthritis and Cartilage 18 (2010) 948e955 953cartilage explants, suggesting a major role for geranylgeranylation
in the pathway leading to cartilage destruction. Thus, our data
strongly indicate that protein geranylgeranylation regulates colla-
genase expression and activity in human osteoarthritic articular
cartilage.
In addition to collagenase expression, we surveyed the simvas-
tatin-mediated response of a number of genes relevant to OA
chondrocyte metabolism. Two aggrecanase enzymes, ADAM-TS5 (a
disintegrin and metalloproteinase with thrombospondin motif
family member 5) and ADAMTS4, have been shown to contribute to
the degradation of aggrecan, the main proteoglycan molecule of
articular cartilage, during OA disease progression1. While the
expression of ADAMTS4was unaffected by statin treatment, ADAM-
TS5 expression was inhibited in a concentration-dependent
manner whether monitored under basal conditions or the
increased levels resulting from cytokine stimulation. In cytokine-
stimulated cartilage explants, both simvastatin and GGTI-2147
inhibited proteoglycan release into the culture supernatants only
during the early phase of the culture (1e3 days). The signiﬁcance of
these ﬁndings is unclear and further explorationwill be required to
determine if selective suppression of ADAM-TS5 expression
through blockade of geranylgeranylation has signiﬁcant conse-
quences on cartilage degradation.
Nitrogen and oxygen-derived free radical-mediated damage of
articular cartilage has long been thought to contribute to OA
disease pathology53,54. Moreover, nitrotyrosine, a product of per-
oxynitrite-mediated tissue damage, has been detected by IHC in
diseased and aged articular cartilage55. The inducible form of
nitric oxide synthase (iNOS) is known to be expressed by chon-
drocytes and to promote apoptotic injury through the over-
production of nitric oxide and the subsequent formation of the
powerful oxidant peroxynitrite, arising from the diffusion-limited
reaction of nitric oxide with superoxide56e58. In fact, iNOS has
been detected in the same OA tissue where nitrotyrosine has been
observed. Interestingly, although iNOS expression was not
decreased by statin treatment in our system, we observed both
a reduction in cartilage damage and a preservation of chondrocyte
viability, observations which may be explained by a reduction in
superoxide production arising from decreased geranylger-
anylation of rac, a key protein of the NADPH oxidase complex59.
This result supports a role for peroxynitrite-mediated injury of
articular chondrocytes in OA.
Another potential effect of statin treatment may be an in situ
reduction in pro-inﬂammatory cytokines. We found that IL-6
expression stimulated by IL-1 treatment is also decreased by sim-
vastatin, with maximum suppression of approximately ﬁfty
percent. This result is interesting in that IL-6 induces MMP-13
expression in chondrocytes13, suggesting that statin treatment may
dampen the positive feedback mechanisms that promote cartilage
degradation in OA. In fact, an apparent increase in the expression
levels of both collagen type II and aggrecan in our chondrocyte
culture system may be an unexpected consequence of the phar-
macological manipulation of the cholesterol pathway by the
statins.
In our hands, we have observed signiﬁcant simvastatin-medi-
ated effects on cytokine-stimulated TIINE production by human
cartilage explants in the micromolar concentration range. After oral
dosing in humans, prolonged joint exposures at these concentra-
tions, akin to the in vitro conditions employed here, would not be
achieved60, which may well be why statins have not been shown to
be efﬁcacious in OA. In fact, such high prolonged systemic expo-
sures would be expected to exacerbate well-known side effects of
statins. One potential solution would be direct intra-articular
injection of a statin, possibly in combination with a sustained
release technology, in order to ensure sufﬁcient exposure ofchondrocytes to the statin while minimizing systemic exposures.
Perhaps most importantly, we have identiﬁed geranylgeranyl
transferase as a key enzyme for modulating MMP-13 expression
and collagenase activity in both human chondrocytes and cartilage
explants. MMP-13 has been shown to play a key role in OA
pathology and speciﬁcally in the joint damage associated with
disease progression. Therefore, an orally bioavailable geranylger-
anyl transferase inhibitor may be able to moderate cartilage
damage in the context of OA while mitigating some of the side
effects of statins that are mediated by other aspects of inhibiting
mevalonate synthesis (e.g., farnesylation). In summary, our studies
provide a mechanistic link between MMP expression and the lipid
intermediates of the cholesterol pathway by identifying ger-
anylgeranylation as a key mechanism contributing to disease
pathogenesis.
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